testing. Accelerate education about genetic risk for primary care providers. Ramp up our support for cancer genetic counselling. Just get it done! MARGARET TEMPERO, MD Margaret Tempero, MD, is a Professor of Medicine and Director of the UCSF
Search Results
they relate to individuals with a personal or family history. The extensive update includes a clarified step-by-step process for the assessment of hereditary CRC syndromes, and a greater emphasis on the importance of genetic counseling. “Many of these
Peter H. Carroll and James L. Mohler
men with high-risk, very high-risk, regional, or metastatic prostate cancer. Men with BRCA1 /2, ATM, PALB2 , or FANCA should be referred for genetic counseling and early use of platinum chemotherapy, or consider enrollment on a clinical trial. 2
Mary B. Daly, Robert Pilarski, Jennifer E. Axilbund, Saundra S. Buys, Beth Crawford, Susan Friedman, Judy E. Garber, Carolyn Horton, Virginia Kaklamani, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer Litton, Lisa Madlensky, P. Kelly Marcom, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Boris Pasche, Gwen Reiser, Kristen Mahoney Shannon, Elizabeth Swisher, Nicoleta C. Voian, Jeffrey N. Weitzel, Alison Whelan, Georgia L. Wiesner, Mary A. Dwyer, and Rashmi Kumar
emphasized that these guidelines were not developed as a substitute for professional genetic counseling. Rather, they are intended to serve as a resource for health care providers to identify individuals who may benefit from cancer risk assessment and genetic
Robert W. Carlson
and supportive care topics. For example, this special edition includes a presentation on “Genetic Counseling in Patients with Familial Risk for Colorectal Cancer,” a topic that was translated into new NCCN Guidelines for Genetic/Familial High
Heather Hampel
their relatives to undergo genetic counseling and testing to learn if they too are at increased risk for cancer and could benefit from intensive cancer surveillance. The costs of screening can be offset by the benefits of cancer prevention in the patient
Kevin Yauy, Marion Imbert-Bouteille, Virginie Bubien, Clothilde Lindet-Bourgeois, Gauthier Rathat, Helene Perrochia, Gaëtan MacGrogan, Michel Longy, Didier Bessis, Julie Tinat, Stéphanie Baert-Desurmont, Maud Blanluet, Pierre Vande Perre, Karen Baudry, Pascal Pujol, and Carole Corsini
be a promising treatment strategy for this cancer. 24 , 25 Offering family genetic testing to relatives of the proband and subsequently setting up personalized medical management is a critical component of cancer genetic counseling. Interestingly
Christina Rybak and Michael J. Hall
provide ongoing comprehensive genetic risk information to current and past patients. Although tumor testing and risk evaluation have become integral aspects of medical oncology care, the complete process of cancer genetic counseling, from the construction
Omalkhair Abulkhair, Nagi Saghir, Lobna Sedky, Ahmed Saadedin, Heba Elzahwary, Neelam Siddiqui, Mervat Al Saleh, Fady Geara, Nuha Birido, Nadia Al-Eissa, Sana Al Sukhun, Huda Abdulkareem, Menar Mohamed Ayoub, Fawaz Deirawan, Salah Fayaz, Alaa Kandil, Sami Khatib, Mufid El-Mistiri, Dorria Salem, El Siah Hassan Sayd, Mohammed Jaloudi, Mohammad Jahanzeb, and William I. Gradishar
). Genetic Counseling for High-Risk Women Recommendations: Setup for infrastructure, genetic counselors, and nurses is encouraged and should be prepared along with laws to protect women and families with positive hereditary factors from discrimination at
NCCN Guidelines Insights: Survivorship, Version 2.2020
Featured Updates to the NCCN Guidelines
Crystal S. Denlinger, Tara Sanft, Javid J. Moslehi, Linda Overholser, Saro Armenian, K. Scott Baker, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Norah Lynn Henry, Christine Hill-Kayser, Melissa Hudson, Nazanin Khakpour, Divya Koura, Allison L. McDonough, Michelle Melisko, Kathi Mooney, Halle C. F. Moore, Natalie Moryl, Tracey O’Connor, Electra D. Paskett, Chirayu Patel, Lindsay Peterson, William Pirl, M. Alma Rodriguez, Kathryn J. Ruddy, Lillie Shockney, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Phyllis Zee, Nicole R. McMillian, and Deborah A. Freedman-Cass
, with genetic counseling and testing as appropriate, is also recommended (see SURV-3 , page 1018). Conclusions Subsequent primary cancers and cardiovascular disease are 2 leading causes of death in cancer survivors. Risk of the former can be mitigated